|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's range||400.45 - 425.44|
|52-week range||269.01 - 425.44|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||25.09|
|Earnings date||20 Oct 2021|
|Forward dividend & yield||4.52 (1.15%)|
|Ex-dividend date||02 Dec 2021|
|1y target est||436.00|
This is Steve Tanal Vice President of Investor Relations and with us this morning on the earnings call are Gail Boudreaux, President and CEO, John Gallina our CFO, Peter Haytaian, President of our Diversified Business Group and IngenioRx; Morgan Kendrick, President of our Commercial and Specialty Business Division and Felicia Norwood, President of our Government Business Division. As a result our focus on reducing health disparities and inequities remains vital to the value Anthem offers their partners [Phonetic].
“Anthem (ANTM) reported a clean EPS and MLR beat, which should further serve to alleviate the fear-trade surrounding managed care medical cost trend. Normalized segment results further reinforce commercial cost pressure vs government cost weakness,” noted Gary Taylor, equity analyst at Cowen.